<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Press Releases

Jump to a page: News Media Kit

Blood-Based Diagnostic Assay Measures Immunotherapy Biomarker PD-L1

Biodesix released data at ASCO-SITC on a new assay that measures PD-L1 in the blood of cancer patients.

Biodesix to Present Study Data: Blood-Based Diagnostic Testing for PD-L1

Biodesix will present data on blood-based diagnostic testing for PD-L1 at ASCO-SITC 2017; ddPCR test measuring mRNA expression from immune and cancer cells

Genestrat Liquid Biopsy Testing™ Now Includes ROS1 and RET Mutations

Biodesix's GeneStrat liquid biopsy test now includes ROS1 and RET mutations. The test helps physicians make treatment decisions for cancer patients.

Clin-TOF Successfully Integrated into VeriStrat® Workflow

Clin-TOF successfully integrated into VeriStrat® workflow

Biodesix® and Bioyong Announce Agreement for Joint Development and Commercialization of VeriStrat® Test in Greater China

Biodesix and Bioyong announced a $38M deal for development and commercialization of VeriStrat in China.

Biodesix® Tests Demonstrate Ability to Stratify Patients Treated with Immunotherapy

Biodesix presents data at the World Lung Conference showing the ability to stratify lung cancer patients treated with immunotherapy

Biodesix® Named Innovative Company of the Year at 2016 IQ Awards

Biodesix won the BizIQ award, 2016 Innovative Company of the Year.

Biodesix’s Diagnostic Cortex™ Platform Used in Three Studies Presented at SITC

The study results indicate that the tests have the potential to offer clinically relevant information that could help physicians selecting immunotherapies for their patients make the best decision

More Information on Disease State and Trial Options for Patients with Advanced Non-Small Cell Lung Cancer; Evaluating Automated and Manual Workflows in cfDNA Extraction

Biodesix, in partnership with BioRad and Qiagen, presents data from new studies at AMP.

Biodesix Presenting Results From Three Studies at SITC Annual Meeting; Oral Poster Presentation, Two Additional Poster Presentations

Biodesix will present data from three studies at SITC's annual meeting.